Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vereirumab
- Development stage
- Unknown
- Lead developer
- Upstream Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Vereirumab (formerly UPB-101) is a human IgG1 kappa monoclonal antibody that targets the Cytokine Receptor-Like Factor 2 (CRLF2), also known as the Thymic Stromal Lymphopoietin receptor (TSLPR). Developed by Upstream Bio, it is currently in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). By binding to CRLF2, vereirumab blocks the signaling of TSLP, an upstream "alarmin" cytokine that triggers multiple downstream inflammatory pathways, including Th2 and Th17 responses. Unlike tezepelumab, which targets the TSLP ligand, vereirumab targets the receptor itself, which may provide more complete or sustained inhibition of the pathway. The drug is designed for subcutaneous administration and aims to provide a long-acting therapeutic option for patients with eosinophilic and non-eosinophilic inflammatory profiles.
- Other names
- human igg1 kappa monoclonal antibody against crlf2anti-TSLPR monoclonal antibody
02
Targets
TSLPR (TSLP receptor)
Beyond the preview
Go deeper on vereirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vereirumab.